CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
DIPROMON focuses on personalizing treatment strategies for bladder cancer using advanced profiling techniques. By integrating patient-specific biomarker data with clinical information, it aims to establish a workflow for optimizing therapeutic interventions tailored to individual patients.
With the advent of Omics technologies capable of profiling substantial fractions of molecular entities from the genome down to the metabolome level a significant boost in understanding disease pathophysiology, consequently providing tailored diagnostics and therapy, was expected.
With impressive results for selected diseases, cancer still sees significant shortcomings.
One reason for this clinical situation is certainly the apparent heterogeneity of cancers, manifesting in clinical presentation…
UNIVERSITY OF SURREY
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
EMERGENTEC BIODEVELOPMENT GMBH
Austria, Wien
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
France, Lyon
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Germany, Braunschweig
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
